Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Tela Bio (TELA) to $5 from $8 and keeps an Overweight rating on the shares following Q3 results. The firm said gross margins were “a little weak” but tight cost controls led to an EBIT loss coming in better than the firm had modeled. Piper told investors in a research note that the stock has been very volatile in recent years but the product is a game-changer and should yield meaningful value creation going forward.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue